{"parse":{"title":"Transmission-based precautions","pageid":30321101,"revid":801017885,"text":{"*":"<div class=\"mw-parser-output\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Further information: <a href=\"/wiki/Isolation_(health_care)\" title=\"Isolation (health care)\">Isolation (health care)</a></div>\n<p><b>Transmission-based precautions</b> are additional <a href=\"/wiki/Infection_control\" title=\"Infection control\">infection control</a> precautions in health care, and the latest routine infection prevention and control practices applied for patients who are known or suspected to be infected or colonized with infectious agents, including certain <a href=\"/wiki/Epidemiology\" title=\"Epidemiology\">epidemiologically</a> important <a href=\"/wiki/Pathogen\" title=\"Pathogen\">pathogens</a>. The latter require additional control measures to effectively prevent transmission.<sup id=\"cite_ref-autogenerated2007_1-0\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#In_history_of_guidelines_for_isolation_precautions_in_hospitals[1]\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">In history of guidelines for isolation precautions in hospitals<sup>&#91;1&#93;</sup></span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Rationale_for_use_in_healthcare_setting\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Rationale for use in healthcare setting</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Contact_precautions\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Contact precautions</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Droplet_precautions\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Droplet precautions</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Airborne_precautions\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">Airborne precautions</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Syndromic_and_empirical_use[1]\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Syndromic and empirical use<sup>&#91;1&#93;</sup></span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Recommendations_for_specific_infections\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Recommendations for specific infections</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Discontinuation\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Discontinuation</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#Application_in_ambulatory_and_home_care_settings\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Application in ambulatory and home care settings</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Footnotes\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Footnotes</span></a></li>\n</ul>\n</div>\n\n<h2><span id=\"In_history_of_guidelines_for_isolation_precautions_in_hospitals.5B1.5D\"></span><span class=\"mw-headline\" id=\"In_history_of_guidelines_for_isolation_precautions_in_hospitals[1]\">In history of guidelines for isolation precautions in hospitals<sup id=\"cite_ref-autogenerated2007_1-1\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup></span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=1\" title=\"Edit section: In history of guidelines for isolation precautions in hospitals[1]\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<td>Year (ref)\n</td>\n<td>Document issued\n</td>\n<td>Comment\n</td></tr>\n<tr>\n<td>1970<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup>\n</td>\n<td>Isolation Technique for Use in Hospitals, 1st ed.\n</td>\n<td>- Introduced seven isolation precaution categories with color-coded cards: Strict, Respiratory, Protective, Enteric, Wound and Skin, Discharge, and Blood - No user decision-making required - Simplicity a strength; over isolation prescribed for some infection\n</td></tr>\n<tr>\n<td>1975<sup id=\"cite_ref-autogenerated1983_4-0\" class=\"reference\"><a href=\"#cite_note-autogenerated1983-4\">&#91;4&#93;</a></sup>\n</td>\n<td>Isolation Techniques for Use in Hospitals, 2nd ed.\n</td>\n<td>- Same conceptual framework as 1st edition\n</td></tr>\n<tr>\n<td>1983<sup id=\"cite_ref-autogenerated1983_4-1\" class=\"reference\"><a href=\"#cite_note-autogenerated1983-4\">&#91;4&#93;</a></sup>\n</td>\n<td>CDC Guideline for Isolation Precautions in Hospitals\n</td>\n<td>- Provided two systems for isolation: category-specific and disease-specific - Protective Isolation eliminated; Blood Precautions expanded to include Body Fluids - Categories included Strict, Contact, Respiratory, AFB, Enteric, Drainage/Secretion, Blood and Body Fluids - Emphasized decision-making by users\n</td></tr>\n<tr>\n<td>1985-88<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</td>\n<td><a href=\"/wiki/Universal_precautions\" title=\"Universal precautions\">Universal precautions</a>\n</td>\n<td>- Developed in response to HIV/AIDS epidemic. - Dictated application of Blood and Body Fluid precautions to all patients, regardless of infection status. - Did not apply to feces, nasal secretions, sputum, sweat, tears, urine, or vomitus unless contaminated by visible blood. - Added personal protective equipment to protect health care workers from mucous membrane exposures. - Handwashing recommended immediately after glove removal. - Added specific recommendations for handling needles and other sharp devices; concept became integral to OSHA\u2019s 1991 rule on occupational exposure to blood-borne pathogens in healthcare settings\n</td></tr>\n<tr>\n<td>1987<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</td>\n<td><a href=\"/wiki/Body_substance_isolation\" title=\"Body substance isolation\">Body substance isolation</a>\n</td>\n<td>- Emphasized avoiding contact with all moist and potentially infectious body substances except sweat even if blood not present. - Shared some features with Universal Precautions. - Weak on infections transmitted by large droplets or by contact with dry surfaces. - Did not emphasize need for special ventilation to contain airborne infections. - Handwashing after glove removal not specified in the absence of visible soiling\n</td></tr>\n<tr>\n<td>1996<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup>\n</td>\n<td>Guideline for Isolation Precautions in Hospitals\n</td>\n<td>- Prepared by the Healthcare Infection Control Practices Advisory Committee (HICPAC). - Melded major features of Universal Precautions and Body Substance Isolation into Standard Precautions to be used with all patients at all times. - Included three transmission-based precaution categories: airborne, droplet, and contact . - Listed clinical syndromes that should dictate use of empiric isolation until an etiological diagnosis is established\n</td></tr></tbody></table>\n<h2><span class=\"mw-headline\" id=\"Rationale_for_use_in_healthcare_setting\">Rationale for use in healthcare setting</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=2\" title=\"Edit section: Rationale for use in healthcare setting\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Communicable diseases occur as a result of the interaction between:\n</p>\n<ul><li>a source (or reservoir) of infectious agents,</li>\n<li>a mode of transmission for the agent,</li>\n<li>a susceptible host with a portal of entry receptive to the agent,</li>\n<li>the environment.</li></ul>\n<p>The control of communicable diseases may involve changing one or more of these components, the first three of which are influenced by the environment. These diseases can have a wide range of effects, varying from silent infection \u2013 with no signs or symptoms \u2013 to severe illness and death. According to its nature, a certain infectious agent may demonstrate one or more following modes of transmission:\n</p>\n<ul><li>direct and indirect contact transmission,</li>\n<li>droplet transmission and</li>\n<li>airborne transmission.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup></li></ul>\n<p>Transmission-based precautions are used when the route(s) of transmission is (are) not completely interrupted using Standard Precautions alone.\nThree categories of transmission-based precautions are designed with respect to the modes of transmission:\n</p>\n<ul><li>Contact precautions,</li>\n<li>Droplet precautions, and</li>\n<li>Airborne precautions.</li></ul>\n<p>For some diseases that have multiple routes of transmission (e.g., SARS), more than one transmission-based precautions category may be used. When used either singly or in combination, they are always used in addition to Standard Precautions.<sup id=\"cite_ref-autogenerated2007_1-2\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup>\n</p><p>When transmission-based precautions are indicated, efforts must be made to counteract possible adverse effects on patients (i.e., anxiety, depression and other mood disturbances,<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> perceptions of stigma,<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> reduced contact with clinical staff,<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> and increases in preventable adverse events<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup> in order to improve acceptance by the patients and adherence by health care workers.\n</p>\n<h3><span class=\"mw-headline\" id=\"Contact_precautions\">Contact precautions</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=3\" title=\"Edit section: Contact precautions\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Contact precautions are intended to prevent transmission of infectious agents, including epidemiologically important <a href=\"/wiki/Microorganism\" title=\"Microorganism\">microorganisms</a>, which are spread by direct or indirect contact with the patient or the patient\u2019s environment. The specific agents and circumstance for which contact precautions are indicated are found in Appendix A \nof the Guidance.<sup id=\"cite_ref-autogenerated2007_1-3\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup> The application of contact precautions for patients infected or colonized with MDROs is described in the 2006 HICPAC/CDC MDRO guideline.<sup id=\"cite_ref-autogenerated2006_18-0\" class=\"reference\"><a href=\"#cite_note-autogenerated2006-18\">&#91;18&#93;</a></sup> Contact precautions also apply where the presence of excessive wound drainage, fecal incontinence, or other discharges from the body suggest an increased potential for extensive environmental contamination and risk of transmission. A single-patient room is preferred for patients who require contact precautions. When a single-patient room is not available, consultation with infection control personnel is recommended to assess the various risks associated with other patient placement options (e.g., cohorting, keeping the patient with an existing roommate). In multi-patient rooms, &gt;3&#160;feet spatial separation between beds is advised to reduce the opportunities for inadvertent sharing of items between the infected/colonized patient and other patients. Healthcare personnel caring for patients on contact precautions wear a gown and gloves for all interactions that may involve contact with the patient or potentially contaminated areas in the patient's environment. Donning PPE upon room entry and discarding before exiting the patient room is done to contain pathogens, especially those that have been implicated in transmission through environmental contamination (e.g., VRE, C. difficile, noroviruses and other intestinal tract pathogens; RSV)<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup><sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup><sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup><sup id=\"cite_ref-recommendations1995_25-0\" class=\"reference\"><a href=\"#cite_note-recommendations1995-25\">&#91;25&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Droplet_precautions\">Droplet precautions</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=4\" title=\"Edit section: Droplet precautions\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Droplet precautions are intended to prevent transmission of pathogens spread through close respiratory or mucous membrane contact with respiratory secretions. Because these pathogens do not remain infectious over long distances in a healthcare facility, special air handling and ventilation are not required to prevent droplet transmission. Infectious agents for which droplet precautions are indicated are found in Appendix A and include <i><a href=\"/wiki/Bordetella_pertussis\" title=\"Bordetella pertussis\">B. pertussis</a></i>, <a href=\"/wiki/Orthomyxoviridae\" title=\"Orthomyxoviridae\">influenza virus</a>, <a href=\"/wiki/Adenovirus\" class=\"mw-redirect\" title=\"Adenovirus\">adenovirus</a>, <a href=\"/wiki/Rhinovirus\" title=\"Rhinovirus\">rhinovirus</a>, <i><a href=\"/wiki/Neisseria_meningitidis\" title=\"Neisseria meningitidis\">N. meningitides</a></i>, and <a href=\"/wiki/Streptococcus_pyogenes\" title=\"Streptococcus pyogenes\">group A streptococcus</a> (for the first 24 hours of antimicrobial therapy). A single patient room is preferred for patients who require droplet precautions. When a single-patient room is not available, consultation with infection control personnel is recommended to assess the various risks associated with other patient placement options (e.g., cohorting, keeping the patient with an existing roommate). Spatial separation of &gt; 3&#160;feet and drawing the curtain between patient beds is especially important for patients in multi-bed rooms with infections transmitted by the droplet route. Healthcare personnel wear a mask (a respirator is not necessary) for close contact with infectious patient; the mask is generally donned upon room entry. Patients on droplet precautions who must be transported outside of the room should wear a mask if tolerated and follow Respiratory Hygiene/Cough Etiquette.\n</p>\n<h3><span class=\"mw-headline\" id=\"Airborne_precautions\">Airborne precautions</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=5\" title=\"Edit section: Airborne precautions\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Airborne precautions prevent transmission of infectious agents that remain infectious over long distances when suspended in the air (e.g., rubeola virus [measles], varicella virus [chickenpox], <i>M. tuberculosis</i>, and possibly SARS-CoV). The preferred placement for patients who require airborne precautions is in an airborne infection isolation room (AIIR). An AIIR is a single-patient room that is equipped with special air handling and ventilation capacity that meet the American Institute of Architects/Facility Guidelines Institute (AIA/FGI) standards for AIIRs (i.e., monitored negative pressure relative to the surrounding area,<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> air exchanges per hour for new construction and renovation and 6 air exchanges per hour for existing facilities, air exhausted directly to the outside or recirculated through HEPA filtration before return).<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup> Some states require the availability of such rooms in hospitals, emergency departments, and nursing homes that care for patients with <i>M. tuberculosis</i>. A respiratory protection program that includes education about use of respirators, <a href=\"/wiki/Respirator_fit_test\" title=\"Respirator fit test\">fit-testing</a>, and user seal checks is required in any facility with AIIRs. In settings where airborne precautions cannot be implemented due to limited engineering resources (e.g., physician offices), masking the patient, placing the patient in a private room (e.g., office examination room) with the door closed, and providing N95 or higher level respirators or masks if respirators are not available for healthcare personnel will reduce the likelihood of airborne transmission until the patient is either transferred to a facility with an AIIR or returned to the home environment, as deemed medically appropriate. Healthcare personnel caring for patients on airborne precautions wear a mask or respirator, depending on the disease-specific recommendations (Appendix A),<sup id=\"cite_ref-autogenerated2007_1-4\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup> that is donned prior to room entry. Whenever possible, non-immune HCWs should not care for patients with vaccine-preventable airborne diseases (e.g., measles, chickenpox, and smallpox).\n</p>\n<h2><span id=\"Syndromic_and_empirical_use.5B1.5D\"></span><span class=\"mw-headline\" id=\"Syndromic_and_empirical_use[1]\">Syndromic and empirical use<sup id=\"cite_ref-autogenerated2007_1-5\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup></span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=6\" title=\"Edit section: Syndromic and empirical use[1]\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Since the infecting agent often is not known at the time of admission to a healthcare facility, transmission-based precautions are used empirically, according to the clinical syndrome and the likely etiologic agents at the time, and then modified when the pathogen is identified or a transmissible infectious etiology is ruled out.\nDiagnosis of many infections requires laboratory confirmation. Since laboratory tests, especially those that depend on culture techniques, often require two or more days for completion, transmission-based precautions must be implemented while test results are pending based on the clinical presentation and likely pathogens. Use of appropriate transmission-based precautions at the time a patient develops symptoms or signs of transmissible infection, or arrives at a healthcare facility for care, reduces transmission opportunities. While it is not possible to identify prospectively all patients needing transmission-based precautions, certain clinical syndromes and conditions carry a sufficiently high risk to warrant their use empirically while confirmatory tests are pending.<sup id=\"cite_ref-autogenerated2007_1-6\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<td>Clinical Syndrome or Condition\u00b9\n</td>\n<td>Potential Pathogens\u00b2\n</td>\n<td>Empiric Precautions (Always includes Standard Precautions)\n</td></tr>\n<tr>\n<td>Diarrhea. Acute diarrhea with a likely infectious cause in an incontinent or diapered patient\n</td>\n<td>Enteric pathogens include enterohemorrhagic <i>Escherichia coli</i> O157:H7, <i>Shigella</i> spp, hepatitis A virus, noroviruses, rotavirus, <i>C. difficile</i>\n</td>\n<td>Contact Precautions (pediatrics and adult)\n</td></tr>\n<tr>\n<td>Meningitis\n</td>\n<td><i>Neisseria meningitidis</i>\n</td>\n<td>Droplet Precautions for first 24 hrs of antimicrobial therapy; mask and face protection for intubation\n</td></tr>\n<tr>\n<td>Meningitis\n</td>\n<td>Enteroviruses <i>M. tuberculosis</i>\n</td>\n<td>Contact Precautions for infants and children\n</td></tr>\n<tr>\n<td>Meningitis\n</td>\n<td><i>M. tuberculosis</i>\n</td>\n<td>Airborne Precautions if pulmonary infiltrate\n<p>Airborne Precautions plus Contact Precautions if potentially infectious draining body fluid present\n</p>\n</td></tr>\n<tr>\n<td>RASH OR EXANTHEMS, GENERALIZED, ETIOLOGY UNKNOWN\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Petechial\" class=\"mw-redirect\" title=\"Petechial\">Petechial</a>/<a href=\"/wiki/Ecchymotic\" class=\"mw-redirect\" title=\"Ecchymotic\">ecchymotic</a> with fever (general)\n</td>\n<td><i>Neisseria meningitides</i>\n</td>\n<td>Droplet Precautions for first 24 hrs of antimicrobial therapy\n</td></tr>\n<tr>\n<td>Ebola, Lassa, Marburg viruses\n</td>\n<td>Droplet Precautions plus Contact Precautions, with face/eye protection, emphasizing safety sharps and barrier precautions when blood exposure likely. Use N95 or higher respiratory protection when aerosol-generating procedure performed\n</td></tr>\n<tr>\n<td>Vesicular\n</td>\n<td>Varicella-zoster, herpes simplex, variola\n</td>\n<td>Airborne plus Contact Precautions;\n</td></tr>\n<tr>\n<td>Vesicular\n</td>\n<td>(smallpox), vaccinia viruses\n</td>\n<td>Contact Precautions only if herpes simplex, localized zoster in an immunocompetent host or vaccinia viruses most likely\n</td></tr>\n<tr>\n<td>Maculopapular with cough, coryza and fever\n</td>\n<td>Rubeola (measles) virus\n</td>\n<td>Airborne Precautions\n</td></tr>\n<tr>\n<td>RESPIRATORY INFECTIONS\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Cough/fever/upper lobe pulmonary infiltrate in an HIV-negative patient or a patient at low risk for human immunodeficiency virus (HIV) infection\n</td>\n<td><i>M. tuberculosis</i>, Respiratory viruses, <i>S. pneumoniae</i>, <i>S. aureus</i> (MSSA or MRSA)\n</td>\n<td>Airborne Precautions plus Contact precautions\n</td></tr>\n<tr>\n<td>Cough/fever/pulmonary infiltrate in any lung location in an HIV-infected patient or a patient at high risk for HIV infection\n</td>\n<td><i>M. tuberculosis</i>, Respiratory viruses, <i>S. pneumoniae</i>, <i>S. aureus</i> (MSSA or MRSA)\n</td>\n<td>Airborne Precautions plus Contact Precautions. Use eye/face protection if aerosol-generating procedure performed or contact with respiratory secretions anticipated.\n<p>If tuberculosis is unlikely and there are no AIIRs and/or respirators available, use Droplet Precautions instead of Airborne Precautions\nTuberculosis more likely in HIV-infected individual than in HIV negative individual\n</p>\n</td></tr>\n<tr>\n<td>Cough/fever/pulmonary infiltrate in any lung location in a patient with a history of recent travel (10\u201321 days) to countries with active outbreaks of SARS, avian influenza\n</td>\n<td><i>M. tuberculosis</i>, severe acute respiratory syndrome virus (SARS-CoV), avian influenza\n</td>\n<td>Airborne plus Contact Precautions plus eye protection.\n<p>If SARS and tuberculosis unlikely, use Droplet Precautions instead of Airborne Precautions.\n</p>\n</td></tr>\n<tr>\n<td>Respiratory infections, particularly bronchiolitis and pneumonia, in infants and young children\n</td>\n<td>Respiratory syncytial virus, parainfluenza virus, adenovirus, influenza virus, Human metapneumovirus\n</td>\n<td>Contact plus Droplet Precautions; Droplet Precautions may be discontinued when adenovirus and influenza have been ruled out\n</td></tr>\n<tr>\n<td>Skin or Wound Infection\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Abscess or draining wound that cannot be covered\n</td>\n<td>Staphylococcus aureus (MSSA or MRSA), group A streptococcus\n</td>\n<td>Contact Precautions. Add Droplet Precautions for the first 24 hours of appropriate antimicrobial therapy if invasive Group A streptococcal disease is suspected\n</td></tr></tbody></table>\n<p>\u00b9 Patients with the syndromes or conditions listed below may present with atypical signs or symptoms (e.g.neonates and adults with pertussis may not have paroxysmal or severe cough). The clinician's index of suspicion should be guided by the prevalence of specific conditions in the community, as well as clinical judgment.\n</p><p>\u00b2 The organisms listed under the column \"Potential Pathogens\" are not intended to represent the complete, or even most likely, diagnoses, but rather possible etiologic agents that require additional precautions beyond Standard Precautions until they can be ruled out.\n</p>\n<h2><span class=\"mw-headline\" id=\"Recommendations_for_specific_infections\">Recommendations for specific infections</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=7\" title=\"Edit section: Recommendations for specific infections\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Details one may find in Appendix A of the Guidance<sup id=\"cite_ref-autogenerated2007_1-7\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<td>Infection or condition\n</td>\n<td>Precautions type\u00b9\n</td>\n<td>Precautions duration\u00b2\n</td>\n<td>Precautions comments\n</td></tr>\n<tr>\n<td>Abscess draining, major\n</td>\n<td>C\n</td>\n<td>DI\n</td>\n<td>No dressing or containment of drainage; until drainage stops or can be contained by dressing\n</td></tr>\n<tr>\n<td>Clostridium difficile\n</td>\n<td>C\n</td>\n<td>DI\n</td>\n<td>Discontinue antibiotics if appropriate. Do not share electronic thermometers;<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup><sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup> ensure consistent environmental cleaning and disinfection. Hypochlorite solutions may be required for cleaning if transmission continues.<sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup> Handwashing with soap and water preferred because of the absence of sporicidal activity of alcohol in waterless antiseptic handrubs<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Acute viral (acute hemorrhagic)\n</td>\n<td>C\n</td>\n<td>DI\n</td>\n<td>Adenovirus most common; enterovirus,<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup><sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> Coxsackie virus A<sup id=\"cite_ref-34\" class=\"reference\"><a href=\"#cite_note-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup>) also associated with community outbreaks. Highly contagious; outbreaks in eye clinics, pediatric and neonatal settings, institutional settings reported. Eye clinics should follow Standard Precautions when handling patients with conjunctivitis. Routine use of infection control measures in the handling of instruments and equipment will prevent the occurrence of outbreaks in this and other settings.<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup><sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup><sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup><sup id=\"cite_ref-39\" class=\"reference\"><a href=\"#cite_note-39\">&#91;39&#93;</a></sup><sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup><sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Diphtheria pharyngeal\n</td>\n<td>D\n</td>\n<td>CN\n</td>\n<td>Until 2 cultures taken 24 hrs. apart negative\n</td></tr>\n<tr>\n<td>Diphtheria cutaneous\n</td>\n<td>C\n</td>\n<td>CN\n</td>\n<td>Until 2 cultures taken 24 hrs. apart negative\n</td></tr>\n<tr>\n<td>Furunculosis, staphylococcal Infants and young children\n</td>\n<td>C\n</td>\n<td>DI\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Rotavirus\n</td>\n<td>C\n</td>\n<td>DI\n</td>\n<td>Ensure consistent environmental cleaning and disinfection and frequent removal of soiled diapers. Prolonged shedding may occur in both immunocompetent and immunocompromised children and the elderly<sup id=\"cite_ref-ReferenceA_42-0\" class=\"reference\"><a href=\"#cite_note-ReferenceA-42\">&#91;42&#93;</a></sup><sup id=\"cite_ref-autogenerated2002_43-0\" class=\"reference\"><a href=\"#cite_note-autogenerated2002-43\">&#91;43&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Hepatitis, viral Type A Diapered or incontinent patients\n</td>\n<td>C\n</td>\n<td>\n</td>\n<td>Maintain Contact Precautions in infants and children &lt;3 years of age for duration of hospitalization; for children 3-14 yrs. of age for 2 weeks after onset of symptoms; &gt;14 yrs. of age for 1 week after onset of symptoms.<sup id=\"cite_ref-44\" class=\"reference\"><a href=\"#cite_note-44\">&#91;44&#93;</a></sup><sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup><sup id=\"cite_ref-46\" class=\"reference\"><a href=\"#cite_note-46\">&#91;46&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Herpes zoster (varicella-zoster) (shingles) Disseminated disease in any patient\n<p>Localized disease in immunocompromised patient until disseminated infection ruled out\n</p>\n</td>\n<td>A,C\n</td>\n<td>DI\n</td>\n<td>Susceptible HCWs should not enter room if immune caregivers are available; no recommendation for protection of immune HCWs; no recommendation for type of protection, i.e. surgical mask or respirator; for susceptible HCWs.\n</td></tr>\n<tr>\n<td>Impetigo\n</td>\n<td>C\n</td>\n<td>U24 hrs\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Influenza human (seasonal influenza)\n</td>\n<td>D\n</td>\n<td>5 days except DI in immunocompromised persons\n</td>\n<td>Single patient room when available or cohort; avoid placement with high-risk patients; mask patient when transported out of room; chemoprophylaxis/vaccine to control/prevent outbreaks.<sup id=\"cite_ref-47\" class=\"reference\"><a href=\"#cite_note-47\">&#91;47&#93;</a></sup> Use gown and gloves according to Standard Precautions may be especially important in pediatric settings. Duration of precautions for immunocompromised patients cannot be defined; prolonged duration of viral shedding (i.e. for several weeks) has been observed; implications for transmission are unknown.<sup id=\"cite_ref-autogenerated2003_48-0\" class=\"reference\"><a href=\"#cite_note-autogenerated2003-48\">&#91;48&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Influenza Avian (e.g. H5N1, H7, H9 strains)\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>See www.cdc.gov/flu/avian/professional/infect-control.htm for current avian influenza guidance.\n</td></tr>\n<tr>\n<td>Pandemic influenza (also a human influenza virus)\n</td>\n<td>D\n</td>\n<td>5 days from onset of symptoms\n</td>\n<td>See <a rel=\"nofollow\" class=\"external free\" href=\"http://www.pandemicflu.gov\">http://www.pandemicflu.gov</a> for current pandemic influenza guidance.\n</td></tr>\n<tr>\n<td>Lice head (pediculosis)\n</td>\n<td>C\n</td>\n<td>U 24 hrs\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Measles (rubeola)\n</td>\n<td>A\n</td>\n<td>4 days after onset of rash; DI in immune compromised\n</td>\n<td>Susceptible HCWs should not enter room if immune care providers are available; no recommendation for face protection for immune HCW; no recommendation for type of face protection for susceptible HCWs, i.e., mask or respirator.<sup id=\"cite_ref-49\" class=\"reference\"><a href=\"#cite_note-49\">&#91;49&#93;</a></sup><sup id=\"cite_ref-50\" class=\"reference\"><a href=\"#cite_note-50\">&#91;50&#93;</a></sup> For exposed susceptibles, post-exposure vaccine within 72 hrs. or immune globulin within 6 days when available.<sup id=\"cite_ref-autogenerated1998_51-0\" class=\"reference\"><a href=\"#cite_note-autogenerated1998-51\">&#91;51&#93;</a></sup><sup id=\"cite_ref-52\" class=\"reference\"><a href=\"#cite_note-52\">&#91;52&#93;</a></sup><sup id=\"cite_ref-53\" class=\"reference\"><a href=\"#cite_note-53\">&#91;53&#93;</a></sup> Place exposed susceptible patients on Airborne precautions and exclude susceptible health care personnel from duty from day 5 after first exposure to day 21 after last exposure, regardless of post-exposure vaccine.<sup id=\"cite_ref-autogenerated1998_51-1\" class=\"reference\"><a href=\"#cite_note-autogenerated1998-51\">&#91;51&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Monkeypox\n</td>\n<td>A,C\n</td>\n<td>A-Until monkeypox confirmed and smallpox excluded C-Until lesions crusted\n</td>\n<td>Use See www.cdc.gov/ncidod/monkeypox for most current recommendations. Transmission in hospital settings unlikely.<sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup> Pre- and post-exposure smallpox vaccine recommended for exposed HCWs\n</td></tr>\n<tr>\n<td>Multidrug-resistant organisms (MDROs), infection or colonization (e.g., MRSA, VRE, VISA/VRSA, ESBLs, resistant S. pneumoniae)\n</td>\n<td>S/C\n</td>\n<td>\n</td>\n<td>MDROs judged by the infection control program, based on local, state, regional, or national recommendations, to be of clinical and epidemiologic significance. Contact Precautions recommended in settings with evidence of ongoing transmission, acute care settings with increased risk for transmission or wounds that cannot be contained by dressings. See recommendations for management options in Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006.<sup id=\"cite_ref-55\" class=\"reference\"><a href=\"#cite_note-55\">&#91;55&#93;</a></sup> Contact state health department for guidance regarding new or emerging MDRO.\n</td></tr>\n<tr>\n<td>Mumps (infectious parotitis)\n</td>\n<td>D\n</td>\n<td>U 9 days\n</td>\n<td>After onset of swelling; susceptible HCWs should not provide care if immune caregivers are available.\n<p>Note: (Recent assessment of outbreaks in healthy 18- to 24-year-olds has indicated that salivary viral shedding occurred early in the course of illness and that 5 days of isolation after onset of parotitis may be appropriate in community settings; however the implications for healthcare personnel and high-risk patient populations remain to be clarified.)\n</p>\n</td></tr>\n<tr>\n<td>Parvovirus B19 (Erythema infectiosum)\n</td>\n<td>D\n</td>\n<td>\n</td>\n<td>Maintain precautions for duration of hospitalization when chronic\n<p>disease occurs in an immunocompromised patient. For patients with transient aplastic crisis or red-cell crisis, maintain precautions for 7 days. Duration of precautions for immunosuppressed patients with persistently positive PCR not defined, but transmission has occurred.<sup id=\"cite_ref-56\" class=\"reference\"><a href=\"#cite_note-56\">&#91;56&#93;</a></sup>\n</p>\n</td></tr>\n<tr>\n<td>Pertussis (whooping cough)\n</td>\n<td>D\n</td>\n<td>U 5 days\n</td>\n<td>Single patient room preferred. Cohorting an option. Post-exposure chemoprophylaxis for household contacts and HCWs with prolonged exposure to respiratory secretions.<sup id=\"cite_ref-57\" class=\"reference\"><a href=\"#cite_note-57\">&#91;57&#93;</a></sup> Recommendations for Tdap vaccine in adults under development.\n</td></tr>\n<tr>\n<td>Plague (<i>Yersinia pestis</i>) Bubonic\n</td>\n<td>S\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td>Plague (<i>Yersinia pestis</i>) Pneumonic\n</td>\n<td>D\n</td>\n<td>U 48 hrs\n</td>\n<td>Antimicrobial prophylaxis for exposed HCW.<sup id=\"cite_ref-58\" class=\"reference\"><a href=\"#cite_note-58\">&#91;58&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Pneumonia Adenovirus\n</td>\n<td>D,C\n</td>\n<td>DI\n</td>\n<td>Outbreaks in pediatric and institutional settings reported.<sup id=\"cite_ref-59\" class=\"reference\"><a href=\"#cite_note-59\">&#91;59&#93;</a></sup><sup id=\"cite_ref-60\" class=\"reference\"><a href=\"#cite_note-60\">&#91;60&#93;</a></sup><sup id=\"cite_ref-61\" class=\"reference\"><a href=\"#cite_note-61\">&#91;61&#93;</a></sup><sup id=\"cite_ref-62\" class=\"reference\"><a href=\"#cite_note-62\">&#91;62&#93;</a></sup> In immunocompromised hosts, extend duration of Droplet and Contact Precautions due to prolonged shedding of virus<sup id=\"cite_ref-ReferenceB_63-0\" class=\"reference\"><a href=\"#cite_note-ReferenceB-63\">&#91;63&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Rubella (German measles) ( also see congenital rubella)\n</td>\n<td>D\n</td>\n<td>U 7 days after onset of rash\n</td>\n<td>Susceptible HCWs should not enter room if immune caregivers are available. No recommendation for wearing face protection (e.g., a surgical mask) if immune. Pregnant women who are not immune should not care for these patients.<sup id=\"cite_ref-autogenerated1998_51-2\" class=\"reference\"><a href=\"#cite_note-autogenerated1998-51\">&#91;51&#93;</a></sup><sup id=\"cite_ref-64\" class=\"reference\"><a href=\"#cite_note-64\">&#91;64&#93;</a></sup> Administer vaccine within three days of exposure to non-pregnant susceptible individuals. Place exposed susceptible patients on Droplet Precautions; exclude susceptible healthcare personnel from duty from day 5 after first exposure to day 21 after last exposure, regardless of post-exposure vaccine\n</td></tr>\n<tr>\n<td>Severe acute respiratory syndrome (SARS)\n</td>\n<td>A,D,C\n</td>\n<td>DI plus 10 days after resolution offever, provided respiratory symptoms are absent or improving\n</td>\n<td>Airborne Precautions preferred; D if AIIR unavailable. N95 or higher respiratory protection; surgical mask if N95 unavailable; eye protection (goggles, face shield); aerosol-generating procedures and \"supershedders\" highest risk for transmission via small droplet nuclei and large droplets.<sup id=\"cite_ref-65\" class=\"reference\"><a href=\"#cite_note-65\">&#91;65&#93;</a></sup><sup id=\"cite_ref-66\" class=\"reference\"><a href=\"#cite_note-66\">&#91;66&#93;</a></sup><sup id=\"cite_ref-67\" class=\"reference\"><a href=\"#cite_note-67\">&#91;67&#93;</a></sup> Vigilant environmental disinfection (see www.cdc.gov/ncidod/sars)\n</td></tr>\n<tr>\n<td>Smallpox\n</td>\n<td>A,C\n</td>\n<td>DI\n</td>\n<td>Until all scabs have crusted and separated (3\u20134 weeks). Non-vaccinated HCWs should not provide care when immune HCWs are available; N95 or higher respiratory protection for susceptible and successfully vaccinated individuals; post-exposure vaccine within 4 days of exposure protective.<sup id=\"cite_ref-68\" class=\"reference\"><a href=\"#cite_note-68\">&#91;68&#93;</a></sup><sup id=\"cite_ref-69\" class=\"reference\"><a href=\"#cite_note-69\">&#91;69&#93;</a></sup><sup id=\"cite_ref-70\" class=\"reference\"><a href=\"#cite_note-70\">&#91;70&#93;</a></sup><sup id=\"cite_ref-71\" class=\"reference\"><a href=\"#cite_note-71\">&#91;71&#93;</a></sup><sup id=\"cite_ref-72\" class=\"reference\"><a href=\"#cite_note-72\">&#91;72&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Streptococcal disease (group A streptococcus) Skin, wound, or burn major\n</td>\n<td>C,D\n</td>\n<td>U 24 hrs\n</td>\n<td>No dressing or dressing does not contain drainage adequately\n</td></tr>\n<tr>\n<td>Tuberculosis (<i>M. tuberculosis</i>) Extrapulmonary, draining lesion)\n</td>\n<td>A,C\n</td>\n<td>\n</td>\n<td>Discontinue precautions only when patient is improving clinically, and drainage has ceased or there are three consecutive negative cultures of continued drainage.<sup id=\"cite_ref-73\" class=\"reference\"><a href=\"#cite_note-73\">&#91;73&#93;</a></sup><sup id=\"cite_ref-74\" class=\"reference\"><a href=\"#cite_note-74\">&#91;74&#93;</a></sup> Examine for evidence of active pulmonary tuberculosis.\n</td></tr>\n<tr>\n<td>Tuberculosis (<i>M. tuberculosis</i>) Pulmonary or laryngeal disease, confirmed\n</td>\n<td>A\n</td>\n<td>\n</td>\n<td>Discontinue precautions only when patient on effective therapy is improving clinically and has three consecutive sputum smears negative for acid-fast bacilli collected on separate days(MMWR 2005; 54: RR-17 <a rel=\"nofollow\" class=\"external free\" href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e\">https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e</a> ) 12.\n</td></tr>\n<tr>\n<td>Varicella Zoster\n</td>\n<td>A,C\n</td>\n<td>Until lesions dry and crusted\n</td>\n<td>Susceptible HCWs should not enter room if immune caregivers are available; no recommendation for face protection of immune HCWs; no recommendation for type of protection, i.e. surgical mask or respirator for susceptible HCWs. In immunocompromised host with varicella pneumonia, prolong duration of precautions for duration of illness. Post-exposure prophylaxis: provide post-exposure vaccine ASAP but within 120 hours; for susceptible exposed persons for whom vaccine is contraindicated (immunocompromised persons, pregnant women, newborns whose mother\u2019s varicella onset is &lt;5 days before delivery or within 48 hrs after delivery) provide VZIG, when available, within 96 hours; if unavailable, use IVIG, Use Airborne Precautions for exposed susceptible persons and exclude exposed susceptible healthcare workers beginning 8 days after first exposure until 21 days after last exposure or 28 if received VZIG, regardless of postexposure vaccination.<sup id=\"cite_ref-75\" class=\"reference\"><a href=\"#cite_note-75\">&#91;75&#93;</a></sup>\n</td></tr>\n<tr>\n<td>Viral hemorrhagic fevers due to Lassa, Ebola, Marburg, Crimean-Congo fever viruses\n</td>\n<td>S,D,C\n</td>\n<td>DI\n</td>\n<td>Single-patient room preferred. Emphasize: 1) use of sharps safety devices and safe work practices, 2) hand hygiene; 3) barrier protection against blood and body fluids upon entry into room (single gloves and fluid-resistant or impermeable gown, face/eye protection with masks, goggles or face shields); and 4) appropriate waste handling. Use N95 or higher respirators when performing aerosol-generating procedures. Largest viral load in final stages of illness when hemorrhage may occur; additional PPE, including double gloves, leg and shoe coverings may be used, especially in resource-limited settings where options for cleaning and laundry are limited. Notify public health officials immediately if Ebola is suspected<sup id=\"cite_ref-recommendations1995_25-1\" class=\"reference\"><a href=\"#cite_note-recommendations1995-25\">&#91;25&#93;</a></sup><sup id=\"cite_ref-76\" class=\"reference\"><a href=\"#cite_note-76\">&#91;76&#93;</a></sup><sup id=\"cite_ref-77\" class=\"reference\"><a href=\"#cite_note-77\">&#91;77&#93;</a></sup><sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup>\n</td></tr></tbody></table>\n<p>1 Type of precautions: A, Airborne precautions; C, Contact; D, Droplet; S, Standard; when A, C, and D are specified, also use S.\n</p><p>\u00b2 Duration of precautions: CN, until off antimicrobial treatment and culture-negative; DI, duration of illness (with wound lesions, DI means until wounds stop draining); DE, until environment completely decontaminated; U, until time specified in hours (hrs) after initiation of effective therapy; Unknown: criteria for establishing eradication of pathogen has not been determined\n</p>\n<h2><span class=\"mw-headline\" id=\"Discontinuation\">Discontinuation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=8\" title=\"Edit section: Discontinuation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Transmission-based precautions remain in effect for limited periods of time (i.e., while the risk for transmission of the infectious agent persists or for the duration of the illness (Appendix A).<sup id=\"cite_ref-autogenerated2007_1-8\" class=\"reference\"><a href=\"#cite_note-autogenerated2007-1\">&#91;1&#93;</a></sup> For most infectious diseases, this duration reflects known patterns of persistence and shedding of infectious agents associated with the natural history of the infectious process and its treatment. For some diseases (e.g., pharyngeal or cutaneous diphtheria, RSV), transmission-based precautions remain in effect until culture or antigen-detection test results document eradication of the pathogen and, for RSV, symptomatic disease is resolved. For other diseases, (e.g., <i>M. tuberculosis</i>) state laws and regulations, and healthcare facility policies, may dictate the duration of precautions 12). In immunocompromised patients, viral shedding can persist for prolonged periods of time (many weeks to months) and transmission to others may occur during that time; therefore, the duration of contact and/or droplet precautions may be prolonged for many weeks.<sup id=\"cite_ref-ReferenceA_42-1\" class=\"reference\"><a href=\"#cite_note-ReferenceA-42\">&#91;42&#93;</a></sup><sup id=\"cite_ref-autogenerated2002_43-1\" class=\"reference\"><a href=\"#cite_note-autogenerated2002-43\">&#91;43&#93;</a></sup><sup id=\"cite_ref-autogenerated2003_48-1\" class=\"reference\"><a href=\"#cite_note-autogenerated2003-48\">&#91;48&#93;</a></sup><sup id=\"cite_ref-ReferenceB_63-1\" class=\"reference\"><a href=\"#cite_note-ReferenceB-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-79\" class=\"reference\"><a href=\"#cite_note-79\">&#91;79&#93;</a></sup><sup id=\"cite_ref-80\" class=\"reference\"><a href=\"#cite_note-80\">&#91;80&#93;</a></sup><sup id=\"cite_ref-81\" class=\"reference\"><a href=\"#cite_note-81\">&#91;81&#93;</a></sup> The duration of contact precautions for patients who are colonized or infected with MDROs remains undefined. MRSA is the only MDRO for which effective decolonization regimens are available.<sup id=\"cite_ref-82\" class=\"reference\"><a href=\"#cite_note-82\">&#91;82&#93;</a></sup> However, carriers of MRSA who have negative nasal cultures after a course of systemic or topical therapy may resume shedding MRSA in the weeks that follow therapy.<sup id=\"cite_ref-83\" class=\"reference\"><a href=\"#cite_note-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-84\" class=\"reference\"><a href=\"#cite_note-84\">&#91;84&#93;</a></sup> Although early guidelines for VRE suggested discontinuation of contact precautions after three stool cultures obtained at weekly intervals proved negative,<sup id=\"cite_ref-recommendations1995_25-2\" class=\"reference\"><a href=\"#cite_note-recommendations1995-25\">&#91;25&#93;</a></sup> subsequent experiences have indicated that such screening may fail to detect colonization that can persist for &gt;1 year.<sup id=\"cite_ref-85\" class=\"reference\"><a href=\"#cite_note-85\">&#91;85&#93;</a></sup><sup id=\"cite_ref-86\" class=\"reference\"><a href=\"#cite_note-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-87\" class=\"reference\"><a href=\"#cite_note-87\">&#91;87&#93;</a></sup><sup id=\"cite_ref-88\" class=\"reference\"><a href=\"#cite_note-88\">&#91;88&#93;</a></sup> Likewise, available data indicate that colonization with VRE, MRSA,<sup id=\"cite_ref-89\" class=\"reference\"><a href=\"#cite_note-89\">&#91;89&#93;</a></sup> and possibly MDR-GNB, can persist for many months, especially in the presence of severe underlying disease, invasive devices, and recurrent courses of antimicrobial agents. It may be prudent to assume that MDRO carriers are colonized permanently and manage them accordingly. Alternatively, an interval free of hospitalizations, antimicrobial therapy, and invasive devices (e.g., 6 or 12 months) before reculturing patients to document clearance of carriage may be used. Determination of the best strategy awaits the results of additional studies. See the 2006 HICPAC/CDC MDRO guideline<sup id=\"cite_ref-autogenerated2006_18-1\" class=\"reference\"><a href=\"#cite_note-autogenerated2006-18\">&#91;18&#93;</a></sup> for discussion of possible criteria to discontinue contact precautions for patients colonized or infected with MDROs.\n</p>\n<h2><span class=\"mw-headline\" id=\"Application_in_ambulatory_and_home_care_settings\">Application in ambulatory and home care settings</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=9\" title=\"Edit section: Application in ambulatory and home care settings\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Although transmission-based precautions generally apply in all healthcare settings, exceptions exist. For example, in home care, AIIRs are not available. Furthermore, family members already exposed to diseases such as varicella and tuberculosis would not use masks or respiratory protection, but visiting HCWs would need to use such protection. Similarly, management of patients colonized or infected with MDROs may necessitate contact precautions in acute care hospitals and in some LTCFs when there is continued transmission, but the risk of transmission in ambulatory care and home care, has not been defined. Consistent use of Standard Precautions may suffice in these settings, but more information is needed.\n</p>\n<h2><span class=\"mw-headline\" id=\"Footnotes\">Footnotes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Transmission-based_precautions&amp;action=edit&amp;section=10\" title=\"Edit section: Footnotes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-autogenerated2007-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated2007_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-autogenerated2007_1-8\"><sup><i><b>i</b></i></sup></a></span> <span class=\"reference-text\">Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\">Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care, WHO Interim Guidelines.2007 p. 53</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">National Communicable Disease Center. Isolation Techniques for Use in Hospitals. 1st ed. Washington, DC: US Government Printing Office;. PHS publication no 2054 1970</span>\n</li>\n<li id=\"cite_note-autogenerated1983-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated1983_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated1983_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Garner JS, Simmons BP. CDC Guideline for Isolation Precautions in Hospitals. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1983. HHS publication no. (CDC) 83-8314. Infect Control 1983;4:245-325.</span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">CDC. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep 1988;37(24):377-82, 87-8.</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">CDC. Recommendations for preventing transmission of infection with human T- lymphotropic virus type III/lymphadenopathy-associated virus in the workplace. MMWR Morb Mortal Wkly Rep 1985;34(450:681-6, 91-5.</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">Lynch P, Jackson MM, Cummings MJ, Stamm WE. Rethinking the role of isolation practices in the prevention of nosocomial infections. Ann Intern Med 1987;107(2):243-6.</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17(1):53-80.(s).</span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\">Bonita, Ruth et al.. Basic epidemiology. 2nd edition. World Health Organization. 226 p., 2006</span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\">Catalano G, Houston SH, Catalano MC, et al. Anxiety and depression in hospitalized patients in resistant organism isolation. South Med J 2003;96(2):141-5.</span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">Tarzi S, Kennedy P, Stone S, Evans M. <a href=\"/wiki/Methicillin-resistant_Staphylococcus_aureus\" title=\"Methicillin-resistant Staphylococcus aureus\">Methicillin-resistant Staphylococcus aureus</a>: psychological impact of hospitalization and isolation in an older adult population. J Hosp Infect 2001;49(4):250-4.</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\">Kelly-Rossini L, Perlman DC, Mason DJ. The experience of respiratory isolation for HIV-infected persons with tuberculosis. J Assoc Nurses AIDS Care 1996;Jan-Feb; 7(1):29-36.</span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\">Knowles HE. The experience of infectious patients in isolation. Nurs Times 1993;89(30):53-6.</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Evans HL, Shaffer MM, Hughes MG, et al. Contact isolation in surgical patients: a barrier to care? Surgery 2003;134(2):180-8.</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\">Kirkland KB, Weinstein JM. Adverse effects of contact isolation. Lancet 1999;354(9185):1177-8.</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\">Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 2003;31(6):354-6.</span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\">Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003;290(14):1899-905.</span>\n</li>\n<li id=\"cite_note-autogenerated2006-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated2006_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated2006_18-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006. 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf</span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\">Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39(2):219-26.</span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\">Bhalla A, Pultz NJ, Gries DM, et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect Control Hosp Epidemiol 2004;25(2):164-7.</span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\">Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 2005;165(3):302-7.</span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\">Hall CB, Douglas RG, Jr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99(1):100-3.</span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\">Evans MR, Meldrum R, Lane W, et al. An outbreak of viral gastroenteritis following environmental contamination at a concert hall. Epidemiol Infect 2002;129(2):355-60.</span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\">Wu HM, Fornek M, Kellogg JS, et al. A Norovirus Outbreak at a Long-Term-Care Facility: The Role of Environmental Surface Contamination. Infect Control Hosp Epidemiol 2005;26(10):802-10.</span>\n</li>\n<li id=\"cite_note-recommendations1995-25\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-recommendations1995_25-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-recommendations1995_25-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-recommendations1995_25-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">CDC. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44 (RR12):1-13.</span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\">CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54(17):1-141.</span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\">AIA. Guidelines for Design and Construction of Hospital and Health Care Facilities. In: American Institute of Architects. Washington, DC: American Institute of Architects Press; 2006.</span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\">Brooks S, Khan A, Stoica D, et al. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect Control Hosp Epidemiol 1998;19(5):333-6.</span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\">Jernigan JA, Siegman-Igra Y, Guerrant RC, Farr BM. A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 1998;19(7):494-9.</span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\">Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003;54(2):109-14.</span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\">Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. Jama 2003;289(10):1274-7.</span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\">Avitzur Y, Amir J. Herpetic whitlow infection in a general pediatrician-an occupational hazard. Infection 2002;30(4):234-6.</span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\">Maitreyi RS, Dar L, Muthukumar A, et al. Acute hemorrhagic conjunctivitis due to enterovirus 70 in India. Emerg Infect Dis 1999;5(2):267-9.</span>\n</li>\n<li id=\"cite_note-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-34\">^</a></b></span> <span class=\"reference-text\">Hall CB. Nosocomial respiratory syncytial virus infections: the \"Cold War\" has not ended. Clin Infect Dis 2000;31(2):590-6.</span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\">CDC. Acute hemorrhagic conjunctivitis outbreak caused by Coxsackievirus A24--Puerto Rico, 2003. MMWR Morb Mortal Wkly Rep 2004;53(28):632-4.</span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\">Montessori V, Scharf S, Holland S, Werker DH, Roberts FJ, Bryce E. Epidemic keratoconjunctivitis outbreak at a tertiary referral eye care clinic. Am J Infect Control 1998;26(4):399-405</span>\n</li>\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\">Buffington J, Chapman LE, Stobierski MG, et al. Epidemic keratoconjunctivitis in a chronic care facility: risk factors and measures for control. J Am Geriatr Soc 1993;41(11):1177-81.</span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\">Jernigan JA, Lowry BS, Hayden FG, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis 1993;167(6):1307-13.</span>\n</li>\n<li id=\"cite_note-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-39\">^</a></b></span> <span class=\"reference-text\">Warren D, Nelson KE, Farrar JA, et al. A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread. J Infect Dis 1989;160(6):938-43.</span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\">Chaberny IE, Schnitzler P, Geiss HK, Wendt C. An outbreak of epidemic keratoconjunctivtis in a pediatric unit due to adenovirus type 8. Infect Control Hosp Epidemiol 2003;24(7):514-9.</span>\n</li>\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\">Faden H, Wynn RJ, Campagna L, Ryan RM. Outbreak of adenovirus type 30 in a neonatal intensive care unit. J Pediatr 2005;146(4):523-7.</span>\n</li>\n<li id=\"cite_note-ReferenceA-42\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ReferenceA_42-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ReferenceA_42-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Wood DJ, David TJ, Chrystie IL, Totterdell B. Chronic enteric virus infection in two T-cell immunodeficient children. J Med Virol 1988;24(4):435-44.</span>\n</li>\n<li id=\"cite_note-autogenerated2002-43\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated2002_43-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated2002_43-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Mori I, Matsumoto K, Sugimoto K, et al. Prolonged shedding of rotavirus in a geriatric inpatient. J Med Virol 2002;67(4):613-5.</span>\n</li>\n<li id=\"cite_note-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-44\">^</a></b></span> <span class=\"reference-text\">COID. 2003 Report of the Committee on Infectious Diseases. In: Redbook. Elk Grove Village, IL: American Academy of Pediatrics; 2003.</span>\n</li>\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\">Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991;164(3):476-82.</span>\n</li>\n<li id=\"cite_note-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-46\">^</a></b></span> <span class=\"reference-text\">Carl M, Kantor RJ, Webster HM, Fields HA, Maynard JE. Excretion of hepatitis A virus in the stools of hospitalized hepatitis patients. J Med Virol 1982;9(2):125-9.</span>\n</li>\n<li id=\"cite_note-47\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-47\">^</a></b></span> <span class=\"reference-text\">CDC. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-8):1-40.</span>\n</li>\n<li id=\"cite_note-autogenerated2003-48\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated2003_48-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated2003_48-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003;348(9):867-8.</span>\n</li>\n<li id=\"cite_note-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-49\">^</a></b></span> <span class=\"reference-text\">Ammari LK, Bell LM, Hodinka RL. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect Control Hosp Epidemiol 1993;14(2):81-6.</span>\n</li>\n<li id=\"cite_note-50\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-50\">^</a></b></span> <span class=\"reference-text\">Behrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. Infect Control Hosp Epidemiol 2003;24(3):202-6.</span>\n</li>\n<li id=\"cite_note-autogenerated1998-51\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-autogenerated1998_51-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-autogenerated1998_51-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-autogenerated1998_51-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchmann SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998;19(6):407-63.</span>\n</li>\n<li id=\"cite_note-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-52\">^</a></b></span> <span class=\"reference-text\">Ruuskanen O, Salmi TT, Halonen P. Measles vaccination after exposure to natural measles. J Pediatr 1978;93(1):43-6.</span>\n</li>\n<li id=\"cite_note-53\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-53\">^</a></b></span> <span class=\"reference-text\">CDC. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47(RR-8):157.</span>\n</li>\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\">Fleischauer AT, Kile JC, Davidson M, et al. Evaluation of human-tohuman transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 2005;40(5):689-94.</span>\n</li>\n<li id=\"cite_note-55\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-55\">^</a></b></span> <span class=\"reference-text\">Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006. CDC, 2006.</span>\n</li>\n<li id=\"cite_note-56\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-56\">^</a></b></span> <span class=\"reference-text\">Lui SL, Luk WK, Cheung CY, Chan TM, Lai KN, Peiris JS. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 2001;71(1):59-64.</span>\n</li>\n<li id=\"cite_note-57\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-57\">^</a></b></span> <span class=\"reference-text\">CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005;54(RR-14):1-16.</span>\n</li>\n<li id=\"cite_note-58\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-58\">^</a></b></span> <span class=\"reference-text\">Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40(8):1166-72.</span>\n</li>\n<li id=\"cite_note-59\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-59\">^</a></b></span> <span class=\"reference-text\">Hatherill M, Levin M, Lawrenson J, Hsiao NY, Reynolds L, Argent A. Evolution of an adenovirus outbreak in a multidisciplinary children's hospital. J Paediatr Child Health 2004;40(8):449-54.</span>\n</li>\n<li id=\"cite_note-60\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-60\">^</a></b></span> <span class=\"reference-text\">Sanchez MP, Erdman DD, Torok TJ, Freeman CJ, Matyas BT. Outbreak of adenovirus 35 pneumonia among adult residents and staff of a chronic care psychiatric facility. J Infect Dis 1997;176(3):760-3.(s).</span>\n</li>\n<li id=\"cite_note-61\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-61\">^</a></b></span> <span class=\"reference-text\">Singh-Naz N, Brown M, Ganeshananthan M. Nosocomial adenovirus infection: molecular epidemiology of an outbreak. Pediatr Infect Dis J 1993;12(11):922-5.</span>\n</li>\n<li id=\"cite_note-62\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-62\">^</a></b></span> <span class=\"reference-text\">Uemura T, Kawashitam T, Ostuka Y, Tanaka Y, Kusubae R, Yoshinaga M. A recent outbreak of adenovirus type 7 infection in a chronic inpatient facility for the severely handicapped. Infect Control Hosp Epidemiol 2000;21(9):559-60.</span>\n</li>\n<li id=\"cite_note-ReferenceB-63\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ReferenceB_63-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ReferenceB_63-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">van Tol MJ, Claas EC, Heemskerk B, et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant 2005;35 Suppl 1:S73-6.</span>\n</li>\n<li id=\"cite_note-64\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-64\">^</a></b></span> <span class=\"reference-text\">Fliegel PE, Weinstein WM. Rubella outbreak in a prenatal clinic: management and prevention. Am J Infect Control 1982;10(1):29-33.</span>\n</li>\n<li id=\"cite_note-65\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-65\">^</a></b></span> <span class=\"reference-text\">Loeb M, McGeer A, Henry B, et al. SARS among critical care nurses, Toronto. Emerg Infect Dis 2004;10(2):251-5.</span>\n</li>\n<li id=\"cite_note-66\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-66\">^</a></b></span> <span class=\"reference-text\">Fowler RA, Guest CB, Lapinsky SE, et al. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med 2004;169(11):1198-202.</span>\n</li>\n<li id=\"cite_note-67\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-67\">^</a></b></span> <span class=\"reference-text\">Scales D, et al. Illness in intensive-care staff after brief exposure to severe acute respiratory syndrome. Emerg Infect Dis 2003;9(10):1205-10.</span>\n</li>\n<li id=\"cite_note-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-68\">^</a></b></span> <span class=\"reference-text\">Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. The epidemiology of smallpox. In: Smallpox and its eradication. Switzerland: World Health Organization; 1988.</span>\n</li>\n<li id=\"cite_note-69\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-69\">^</a></b></span> <span class=\"reference-text\">Gelfand HM, Posch J. The recent outbreak of smallpox in Meschede, West Germany. Am J Epidemiol 1971;93(4):234-7.</span>\n</li>\n<li id=\"cite_note-70\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-70\">^</a></b></span> <span class=\"reference-text\">CDC. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001;50(RR-10):1-25; quiz CE1-7.</span>\n</li>\n<li id=\"cite_note-71\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-71\">^</a></b></span> <span class=\"reference-text\">Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003;37(2):241-50.</span>\n</li>\n<li id=\"cite_note-72\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-72\">^</a></b></span> <span class=\"reference-text\">Dixon CW. Smallpox in Tripolitania, 1946: an epidemiological and clinical study of 500 cases, including trials of penicillin treatment. . J Hyg (Lond) 1948;46:351-77.</span>\n</li>\n<li id=\"cite_note-73\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-73\">^</a></b></span> <span class=\"reference-text\">Hutton MD, Stead WW, Cauthen GM, Bloch AB, Ewing WM. Nosocomial transmission of tuberculosis associated with a draining abscess. J Infect Dis 1990;161(2):286-95.</span>\n</li>\n<li id=\"cite_note-74\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-74\">^</a></b></span> <span class=\"reference-text\">Frampton MW. An outbreak of tuberculosis among hospital personnel caring for a patient with a skin ulcer. Ann Intern Med 1992;117(4):312-3.</span>\n</li>\n<li id=\"cite_note-75\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-75\">^</a></b></span> <span class=\"reference-text\">Watson B, Seward J, Yang A, et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105(1 Pt 1):84-8.</span>\n</li>\n<li id=\"cite_note-76\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-76\">^</a></b></span> <span class=\"reference-text\">Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287(18):2391-405.</span>\n</li>\n<li id=\"cite_note-77\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-77\">^</a></b></span> <span class=\"reference-text\"><a href=\"/w/index.php?title=Www.bt.cdc.gov/agent/vhf/&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Www.bt.cdc.gov/agent/vhf/ (page does not exist)\">www.bt.cdc.gov/agent/vhf/</a></span>\n</li>\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\">CDC. Emergency Preparedness &amp; Response. wwwbtcdcgov 2003.</span>\n</li>\n<li id=\"cite_note-79\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-79\">^</a></b></span> <span class=\"reference-text\">Zambon M, Bull T, Sadler CJ, Goldman JM, Ward KN. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998;36(8):2289-93.</span>\n</li>\n<li id=\"cite_note-80\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-80\">^</a></b></span> <span class=\"reference-text\">Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315(2):77-81.</span>\n</li>\n<li id=\"cite_note-81\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-81\">^</a></b></span> <span class=\"reference-text\">Lui SL, Luk WK, Cheung CY, Chan TM, Lai KN, Peiris JS. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 2001;71(1):59-64</span>\n</li>\n<li id=\"cite_note-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-82\">^</a></b></span> <span class=\"reference-text\">Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect 2001;48 Suppl A:S9-14.</span>\n</li>\n<li id=\"cite_note-83\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-83\">^</a></b></span> <span class=\"reference-text\">Cederna JE, Terpenning MS, Ensberg M, Bradley SF, Kauffman CA. Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol 1990;11(1):13-6.</span>\n</li>\n<li id=\"cite_note-84\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-84\">^</a></b></span> <span class=\"reference-text\">Kauffman CA, Terpenning MS, He X, et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med 1993;94(4):371-8.</span>\n</li>\n<li id=\"cite_note-85\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-85\">^</a></b></span> <span class=\"reference-text\">Bonten MJ, Slaughter S, Ambergen AW, et al. The role of \"colonization pressure\" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158(10):1127-32.</span>\n</li>\n<li id=\"cite_note-86\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-86\">^</a></b></span> <span class=\"reference-text\">Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16(12):680-5.</span>\n</li>\n<li id=\"cite_note-87\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-87\">^</a></b></span> <span class=\"reference-text\">D'Agata EM, et al. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002;34(2):167-72.</span>\n</li>\n<li id=\"cite_note-88\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-88\">^</a></b></span> <span class=\"reference-text\">Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002;23(8):436-40.</span>\n</li>\n<li id=\"cite_note-89\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-89\">^</a></b></span> <span class=\"reference-text\">Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001;32(10):1393-8.</span>\n</li>\n</ol></div>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Health_care\" style=\"padding:3px\"><table class=\"nowraplinks hlist collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Health_care\" title=\"Template:Health care\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Health_care\" title=\"Template talk:Health care\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Health_care&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Health_care\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Health_care\" title=\"Health care\">Health care</a></div></th></tr><tr><td class=\"navbox-abovebelow\" colspan=\"2\"><div id=\"*_Economics&amp;#10;*_Equipment&amp;#10;*_Guidelines&amp;#10;*_Industry&amp;#10;*_Philosophy&amp;#10;*_Policy&amp;#10;*_Providers&amp;#10;*_Ranking&amp;#10;*_Reform&amp;#10;*_System\">\n<ul><li><a href=\"/wiki/Health_economics\" title=\"Health economics\">Economics</a></li>\n<li><a href=\"/wiki/Medical_equipment\" title=\"Medical equipment\">Equipment</a></li>\n<li><a href=\"/wiki/Medical_guideline\" title=\"Medical guideline\">Guidelines</a></li>\n<li><a href=\"/wiki/Health_care_industry\" class=\"mw-redirect\" title=\"Health care industry\">Industry</a></li>\n<li><a href=\"/wiki/Philosophy_of_healthcare\" title=\"Philosophy of healthcare\">Philosophy</a></li>\n<li><a href=\"/wiki/Health_policy\" title=\"Health policy\">Policy</a></li>\n<li><a href=\"/wiki/Health_care_provider\" class=\"mw-redirect\" title=\"Health care provider\">Providers</a></li>\n<li><a href=\"/wiki/WHO%27s_ranking_of_health_care_systems\" class=\"mw-redirect\" title=\"WHO&#39;s ranking of health care systems\">Ranking</a></li>\n<li><a href=\"/wiki/Health_care_reform\" title=\"Health care reform\">Reform</a></li>\n<li><a href=\"/wiki/Health_system\" title=\"Health system\">System</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Professions</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Medicine\" title=\"Medicine\">Medicine</a></li>\n<li><a href=\"/wiki/Nursing\" title=\"Nursing\">Nursing</a></li>\n<li><a href=\"/wiki/Healthcare_science\" class=\"mw-redirect\" title=\"Healthcare science\">Healthcare science</a></li>\n<li><a href=\"/wiki/Dentistry\" title=\"Dentistry\">Dentistry</a></li>\n<li><a href=\"/wiki/Allied_health_professions\" title=\"Allied health professions\">Allied health professions</a></li>\n<li><a href=\"/wiki/Pharmacy\" title=\"Pharmacy\">Pharmacy</a></li>\n<li><a href=\"/wiki/Health_information_management\" title=\"Health information management\">Health information management</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Settings</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Assisted_living\" title=\"Assisted living\">Assisted living</a></li>\n<li><a href=\"/wiki/Clinic\" title=\"Clinic\">Clinic</a></li>\n<li><a href=\"/wiki/Hospital\" title=\"Hospital\">Hospital</a></li>\n<li><a href=\"/wiki/Nursing_home\" class=\"mw-redirect\" title=\"Nursing home\">Nursing home</a></li>\n<li><a href=\"/wiki/Medical_school\" title=\"Medical school\">Medical school</a> (<a href=\"/wiki/Academic_health_science_centre\" title=\"Academic health science centre\">Academic health science centre</a>, <a href=\"/wiki/Teaching_hospital\" title=\"Teaching hospital\">Teaching hospital</a>)</li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Care</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Acute_care\" title=\"Acute care\">Acute</a></li>\n<li><a href=\"/wiki/Chronic_care\" title=\"Chronic care\">Chronic</a></li>\n<li><a href=\"/wiki/End-of-life_care\" title=\"End-of-life care\">End-of-life</a></li>\n<li><a href=\"/wiki/Hospice\" title=\"Hospice\">Hospice</a></li>\n<li><a href=\"/wiki/Overutilization\" class=\"mw-redirect\" title=\"Overutilization\">Overutilization</a></li>\n<li><a href=\"/wiki/Palliative_care\" title=\"Palliative care\">Palliative</a></li>\n<li><a href=\"/wiki/Primary_care\" title=\"Primary care\">Primary</a></li>\n<li><a href=\"/wiki/Self_care\" class=\"mw-redirect\" title=\"Self care\">Self</a></li>\n<li><a href=\"/wiki/Total_care\" title=\"Total care\">Total</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Skills / Training</th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Doctor-patient_relationship#Bedside_manner\" class=\"mw-redirect\" title=\"Doctor-patient relationship\">Bedside manner</a></li>\n<li><a href=\"/wiki/Cultural_competence_in_health_care\" class=\"mw-redirect\" title=\"Cultural competence in health care\">Cultural competence</a></li>\n<li><a href=\"/wiki/Medical_diagnosis\" title=\"Medical diagnosis\">Diagnosis</a></li>\n<li><a href=\"/wiki/Medical_education\" title=\"Medical education\">Education</a></li>\n<li><a href=\"/wiki/Universal_precautions\" title=\"Universal precautions\">Universal precautions</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">By country</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Health_care_in_the_United_States\" title=\"Health care in the United States\">United States</a>\n<ul><li><a href=\"/wiki/Healthcare_reform_debate_in_the_United_States\" title=\"Healthcare reform debate in the United States\">reform debate in the United States</a></li></ul></li>\n<li><a href=\"/wiki/Health_care_in_the_United_Kingdom\" title=\"Health care in the United Kingdom\">United Kingdom</a></li>\n<li><a href=\"/wiki/Health_care_in_Canada\" class=\"mw-redirect\" title=\"Health care in Canada\">Canada</a></li>\n<li><a href=\"/wiki/Health_care_in_Australia\" title=\"Health care in Australia\">Australia</a></li>\n<li><a href=\"/wiki/Health_care_in_New_Zealand\" title=\"Health care in New Zealand\">New Zealand</a></li>\n<li><a href=\"/wiki/Category:Healthcare_by_country\" title=\"Category:Healthcare by country\">(Category Healthcare by country)</a></li></ul>\n</div></td></tr><tr><td class=\"navbox-abovebelow\" colspan=\"2\"><div>\n<ul><li><img alt=\"Category\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/16px-Folder_Hexagonal_Icon.svg.png\" title=\"Category\" width=\"16\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/24px-Folder_Hexagonal_Icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/48/Folder_Hexagonal_Icon.svg/32px-Folder_Hexagonal_Icon.svg.png 2x\" data-file-width=\"36\" data-file-height=\"31\" /> <a href=\"/wiki/Category:Health_care\" title=\"Category:Health care\">Category</a></li></ul>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw2229\nCached time: 20180918015853\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.220 seconds\nReal time usage: 0.244 seconds\nPreprocessor visited node count: 1148/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 14024/2097152 bytes\nTemplate argument size: 126/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 39216/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.018/10.000 seconds\nLua memory usage: 950 KB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  158.630      1 -total\n 25.04%   39.722      1 Template:Reflist\n 19.59%   31.079      1 Template:See\n 12.35%   19.597      1 Template:Health_care\n 10.52%   16.688      1 Template:Navbox\n  4.71%    7.472      1 Template:Icon\n  1.19%    1.889      1 Template:Column-width\n  1.10%    1.750      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:30321101-0!canonical and timestamp 20180918015853 and revision id 801017885\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"Epidemiology"},{"sortkey":"","*":"Medical_hygiene"},{"sortkey":"","*":"Infectious_diseases"},{"sortkey":"","*":"Public_health"}],"links":[{"ns":10,"exists":"","*":"Template:Health care"},{"ns":0,"exists":"","*":"Academic health science centre"},{"ns":0,"exists":"","*":"Acute care"},{"ns":0,"exists":"","*":"Adenovirus"},{"ns":0,"exists":"","*":"Allied health professions"},{"ns":0,"exists":"","*":"Assisted living"},{"ns":0,"exists":"","*":"Body substance isolation"},{"ns":0,"exists":"","*":"Bordetella pertussis"},{"ns":0,"exists":"","*":"Chronic care"},{"ns":0,"exists":"","*":"Clinic"},{"ns":0,"exists":"","*":"Cultural competence in health care"},{"ns":0,"exists":"","*":"Dentistry"},{"ns":0,"exists":"","*":"Doctor-patient relationship"},{"ns":0,"exists":"","*":"Ecchymotic"},{"ns":0,"exists":"","*":"End-of-life care"},{"ns":0,"exists":"","*":"Epidemiology"},{"ns":0,"exists":"","*":"Health care"},{"ns":0,"exists":"","*":"Health care in Australia"},{"ns":0,"exists":"","*":"Health care in Canada"},{"ns":0,"exists":"","*":"Health care in New Zealand"},{"ns":0,"exists":"","*":"Health care in the United Kingdom"},{"ns":0,"exists":"","*":"Health care in the United States"},{"ns":0,"exists":"","*":"Health care industry"},{"ns":0,"exists":"","*":"Health care provider"},{"ns":0,"exists":"","*":"Health care reform"},{"ns":0,"exists":"","*":"Health economics"},{"ns":0,"exists":"","*":"Health information management"},{"ns":0,"exists":"","*":"Health policy"},{"ns":0,"exists":"","*":"Health system"},{"ns":0,"exists":"","*":"Healthcare reform debate in the United States"},{"ns":0,"exists":"","*":"Healthcare science"},{"ns":0,"exists":"","*":"Hospice"},{"ns":0,"exists":"","*":"Hospital"},{"ns":0,"exists":"","*":"Infection control"},{"ns":0,"exists":"","*":"Isolation (health care)"},{"ns":0,"exists":"","*":"Medical diagnosis"},{"ns":0,"exists":"","*":"Medical education"},{"ns":0,"exists":"","*":"Medical equipment"},{"ns":0,"exists":"","*":"Medical guideline"},{"ns":0,"exists":"","*":"Medical school"},{"ns":0,"exists":"","*":"Medicine"},{"ns":0,"exists":"","*":"Methicillin-resistant Staphylococcus aureus"},{"ns":0,"exists":"","*":"Microorganism"},{"ns":0,"exists":"","*":"Neisseria meningitidis"},{"ns":0,"exists":"","*":"Nursing"},{"ns":0,"exists":"","*":"Nursing home"},{"ns":0,"exists":"","*":"Orthomyxoviridae"},{"ns":0,"exists":"","*":"Overutilization"},{"ns":0,"exists":"","*":"Palliative care"},{"ns":0,"exists":"","*":"Pathogen"},{"ns":0,"exists":"","*":"Petechial"},{"ns":0,"exists":"","*":"Pharmacy"},{"ns":0,"exists":"","*":"Philosophy of healthcare"},{"ns":0,"exists":"","*":"Primary care"},{"ns":0,"exists":"","*":"Respirator fit test"},{"ns":0,"exists":"","*":"Rhinovirus"},{"ns":0,"exists":"","*":"Self care"},{"ns":0,"exists":"","*":"Streptococcus pyogenes"},{"ns":0,"exists":"","*":"Teaching hospital"},{"ns":0,"exists":"","*":"Total care"},{"ns":0,"exists":"","*":"Universal precautions"},{"ns":0,"exists":"","*":"WHO's ranking of health care systems"},{"ns":0,"*":"Www.bt.cdc.gov/agent/vhf/"},{"ns":11,"exists":"","*":"Template talk:Health care"},{"ns":14,"exists":"","*":"Category:Health care"},{"ns":14,"exists":"","*":"Category:Healthcare by country"}],"templates":[{"ns":10,"exists":"","*":"Template:See"},{"ns":10,"exists":"","*":"Template:Further"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Health care"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":10,"exists":"","*":"Template:Icon"},{"ns":828,"exists":"","*":"Module:Labelled list hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:Icon"},{"ns":828,"exists":"","*":"Module:Icon/data"}],"images":["Folder_Hexagonal_Icon.svg"],"externallinks":["http://www.pandemicflu.gov","https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e"],"sections":[{"toclevel":1,"level":"2","line":"In history of guidelines for isolation precautions in hospitals<sup>&#91;1&#93;</sup>","number":"1","index":"1","fromtitle":"Transmission-based_precautions","byteoffset":876,"anchor":"In_history_of_guidelines_for_isolation_precautions_in_hospitals[1]"},{"toclevel":1,"level":"2","line":"Rationale for use in healthcare setting","number":"2","index":"2","fromtitle":"Transmission-based_precautions","byteoffset":4808,"anchor":"Rationale_for_use_in_healthcare_setting"},{"toclevel":2,"level":"3","line":"Contact precautions","number":"2.1","index":"3","fromtitle":"Transmission-based_precautions","byteoffset":7879,"anchor":"Contact_precautions"},{"toclevel":2,"level":"3","line":"Droplet precautions","number":"2.2","index":"4","fromtitle":"Transmission-based_precautions","byteoffset":11120,"anchor":"Droplet_precautions"},{"toclevel":2,"level":"3","line":"Airborne precautions","number":"2.3","index":"5","fromtitle":"Transmission-based_precautions","byteoffset":12677,"anchor":"Airborne_precautions"},{"toclevel":1,"level":"2","line":"Syndromic and empirical use<sup>&#91;1&#93;</sup>","number":"3","index":"6","fromtitle":"Transmission-based_precautions","byteoffset":15146,"anchor":"Syndromic_and_empirical_use[1]"},{"toclevel":1,"level":"2","line":"Recommendations for specific infections","number":"4","index":"7","fromtitle":"Transmission-based_precautions","byteoffset":20633,"anchor":"Recommendations_for_specific_infections"},{"toclevel":1,"level":"2","line":"Discontinuation","number":"5","index":"8","fromtitle":"Transmission-based_precautions","byteoffset":40794,"anchor":"Discontinuation"},{"toclevel":1,"level":"2","line":"Application in ambulatory and home care settings","number":"6","index":"9","fromtitle":"Transmission-based_precautions","byteoffset":45647,"anchor":"Application_in_ambulatory_and_home_care_settings"},{"toclevel":1,"level":"2","line":"Footnotes","number":"7","index":"10","fromtitle":"Transmission-based_precautions","byteoffset":46416,"anchor":"Footnotes"}],"parsewarnings":[],"displaytitle":"Transmission-based precautions","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q7834606"}]}}